Dyadic Applied BioSolutions

Dyadic Applied BioSolutions is a global biotechnology company headquartered in Jupiter, Florida, with operations in the United States and a satellite office in Wageningen, Netherlands. The company develops, manufactures, and commercializes precision-engineered, animal-free recombinant proteins and enzymes for life sciences, food and nutrition, and bio-industrial markets. Products are produced using the company’s proprietary microbial expression platforms, C1 and Dapibus™. The business model includes direct product sales, distribution partnerships, manufacturing collaborations, and technology licensing (annual fees, milestones, development funding, product supply revenues, and revenue-sharing arrangements).

Platform capabilities

C1 Protein Production Platform

• Thermophilic fungus-based platform (Thermothelomyces heterothallica) engineered for high-yield, scalable protein production.
• Designed to reduce costs, shorten development timelines, and simplify downstream purification; avoids some requirements typical of mammalian systems (for example, viral and endotoxin concerns).
• Historically used for industrial enzymes and now developed for pharmaceutical applications, with rights to sublicense for human and animal pharmaceuticals (subject to terms). Danisco retains certain rights and royalties may be owed in some cases.
• Used in vaccine, monoclonal antibody, and complex biologics programs and validated through multiple funded collaborations and non-dilutive programs (Gates Foundation, CEPI/FBS FAST, NIH/NIAID programs, Scripps RSV antigens, CEPI avian influenza work, and others).

Dapibus™ Protein Production Platform

• Proprietary microbial platform for high-value, non-animal proteins and enzymes across Life Sciences, Food & Nutrition, and Bio-Industrial markets.
• Targets faster development, lower production costs, and simpler regulatory pathways relative to therapeutic biologics.
• Commercialization of several Dapibus-enabled products began in 2026 through partnerships and internal manufacturing initiatives.

Genome editing and optimization

• In 2025 the company licensed CRISPR/Cas9 tools from ERS Genomics to support strain engineering and production optimization on both platforms.

Markets and products (pipeline highlights)

Life Sciences

• Recombinant serum albumin (AlbuFree™ DX) developed with Proliant Health and Biologicals; commercial launch in 2026 for research and diagnostic use. Dyadic receives profit share and development/milestone payments.
• Recombinant transferrin and fibroblast growth factor (FGF); RNase-free DNase I launched in 2026 through collaboration with Fermbox.
• Expanded RNA/DNA enzyme portfolio under development, including RNase inhibitors, T7 RNAP, DNA ligase, and polymerases.

Food & Nutrition

• Non-animal dairy proteins and enzymes, including alpha-lactalbumin, lactoferrin, and caseins, plus dairy-processing enzymes.
• Casein variants have been produced; collaboration with BRIG BIO (December 2025) to develop and license recombinant bovine alpha-lactalbumin, with BRIG BIO funding development and receiving global license rights.

Bio-Industrial

• Enzymes for biomass conversion and agricultural residue processing (EN3ZYME™) developed with Fermbox. Collaboration expanded in December 2025 to accelerate development and commercialization across markets.

Funded programs and partnerships

• Gates Foundation (2024): ~US$3.1M for C1-produced monoclonal antibodies for RSV and malaria.
• CEPI/FBS FAST and European Vaccine Hub programs (2025): up to ~US$2.4M to support rapid antigen development and pandemic preparedness.
• NIAID/NIH LMIV: technology transfer for malaria vaccine development, with BARDA engagement.
• Scripps Research Institute: expression of prefusion RSV antigens with immunogenicity data.
• CEPI/FBS avian influenza programs: H5 antigens produced and under preclinical evaluation.
• Additional collaborations include Uvax Bio, AdaptVac, and EUROSTARS RABIVA, with equity and royalty arrangements in some cases.

Strategic collaborations and licenses

• Rubic One Health (April 2023; expanded 2024): vaccines and therapeutics for human and animal health in underserved African markets.
• Abic/Phibro sublicense for livestock vaccines and treatments (expanded 2024).
• VTT Technical Research Centre of Finland: collaboration since 2016 on safety, productivity, and glycoengineering initiatives.
• Fermbox: ongoing collaboration for animal-free proteins and enzymes, including EN3ZYME and DNase I products with revenue-sharing arrangements.

Customer and revenue profile (as of 2025 year-end)

• Customers: 14 in 2025 (19 in 2024).
• Revenue concentration: two customers accounted for approximately $1,859,000 (about 60.1% of revenue) in 2025; in 2024 two customers accounted for approximately $1,915,000 (about 54.8%).
• 2025 revenue: approximately $3.1 million.
• Accounts receivable: from four customers in 2025 and nine customers in 2024.
• Revenue streams include direct product sales, distribution partnerships, manufacturing collaborations, and licensing arrangements (upfronts, milestones, royalties, development funding, and revenue sharing).

Employees and facilities

• Employees: 5 full-time employees as of December 31, 2025, all located in the United States.
• Principal locations:
  • Global headquarters: 1044 N US 1, Jupiter, Florida. Lease through August 31, 2026, with two successive one-year extension options. Base rent approximately $59,000 per year plus common-area charges and 3% annual increases.
  • Netherlands office: Wageningen, Netherlands. Lease expiring January 31, 2027; annual rent approximately $5,000.

Intellectual property

• Patent portfolio: six patent families owned or exclusively licensed, with national-phase filings initiated.
• US: 2 issued patents and 4 pending US patent applications.
• Other issued patents: Russia (1) and South Africa (1).
• Additional filings: 28 patent applications in Europe, China, and other jurisdictions.
• Protection strategy: patents for C1 and Dapibus platforms and related production methods, supported by trade secrets and confidential information.
• Patent-related risks: protection can be challenged; third-party patents may require licenses; potential for infringement claims.

Corporate branding and capital

• Rebranding: began doing business as Dyadic Applied BioSolutions effective August 1, 2025.
• Corporate status: smaller reporting company. Recent underwritten equity offering in August 2025 raised net proceeds of approximately $4.9 million.

Financial condition and outlook

• Accumulated deficit: approximately $93.5 million as of December 31, 2025.
• Profitability: history of net losses; current profitability has not been achieved. Near-term profitability depends on licensing agreements, collaborations, and product revenues.
• Funding needs: additional funding required to expand R&D, manufacturing capabilities, and commercialization efforts; potential future equity or debt financing may result in dilution.
• Market and liquidity considerations: customer and revenue concentration, regulatory and development risks, and reliance on third-party collaborations and contract service providers.

Regulatory and other considerations

• Regulatory environment: subject to FDA and international regulatory regimes for pharmaceutical and non-pharmaceutical products. GRAS determinations and other safety or regulatory submissions may be required for some products.
• Sustainability and governance: emphasis on animal-free production and sustainability, and attention to evolving regulatory and public views on genetically engineered organisms.

Summary Dyadic Applied BioSolutions develops and commercializes animal-free recombinant proteins and enzymes using the C1 and Dapibus platforms. The company targets life sciences, food and nutrition, and bio-industrial markets while continuing to validate C1 for pharmaceutical applications. It operates with a small in-house team, a network of third-party partners for R&D and manufacturing, modest revenue in 2025, and a substantial accumulated deficit, and is transitioning toward a commercially focused, multi-market biotechnology company.